PharmaSGP Holding SE
XETRA:PSG
PharmaSGP Holding SE
XETRA:PSG
Price:
22.8 EUR
-0.87%
Market Closed
Updated:
May 6, 2024
PharmaSGP Holding SE
Operating Income
|
PharmaSGP Holding SE
Operating Income Peer Comparison
Comparables:
ATAI
BAYN
MRK
93M1
DMP
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Operating Income
€17.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Operating Income
-$125.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Operating Income
€8.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Merck KGaA
XETRA:MRK
|
Operating Income
€4.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Operating Income
-€975.1k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Operating Income
€201m
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
See Also
What is PharmaSGP Holding SE's Operating Income?
Operating Income
17.8m
EUR
17.8m
EUR
Based on the financial report for Dec 31, 2022, PharmaSGP Holding SE's Operating Income amounts to 17.8m EUR.
What is PharmaSGP Holding SE's Operating Income growth rate?
Operating Income CAGR 5Y
3%
3%
Over the last year, the Operating Income growth was 13%. The average annual Operating Income growth rates for PharmaSGP Holding SE have been -7% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
